All In Biotech

Drug Trial Radar · NCT01170286

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects

Last checked: Nov 19, 2026Latest source record: Mar 23, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Jul 2010

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
DBV TechnologiesIndustry
Sponsor type
Industry
First posted
Jul 27, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.

Conditions

  • Peanut Allergy

Interventions

  • Whole peanut extractBiological

    Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.

  • Placebo formulationBiological

    Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluationTime frame: Safety evaluation to be performed at each visit during the 2-week treatment and at the follow-up visit one week after the end of treatment.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • National Jewish Health

    Denver, Colorado

  • CRI Worldwide

    Willingboro, New Jersey

  • Duke University Medical Center

    Durham, North Carolina

  • Aspen Clinical Research

    Orem, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.